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Summary 
A central issue in the pathogenesis of Alzheimer's dis- 
ease (AD) is the relationship between amyloid deposi- 
tion and neurofibrillary tangle formation. To determine 
whether amyloid fibril formation affects the phosphor- 
ylation state of tau, primary cultures of fetal rat hippo- 
campal and human cortical neurons were treated with 
p-amyloid (pA) in a soluble, amorphous-aggregated, 
or fibrillar form. Fibrillar pA, but not soluble or amor- 
phous-aggregated 13A, markedly induces the phos- 
phorylation of tau at Ser-202 and Ser-396/Ser-404, re- 
sulting in a shift in the tau M, in human cortical 
neurons. Hyperphosphorylated tau accumulates in the 
somatodendritic compartment of fibrillar l~A-treated 
neurons in a soluble form that is not associated with 
microtubules and is incapable of binding to microtu- 
bules in vitro. Dephosphorylation of pA-induced tau 
restores its capacity to bind to microtubules. Thus, 
amyloid fibril formation alters the phosphorylation 
state of tau, resulting in the loss of microtubule binding 
capacity and somatodendritic accumulation, proper- 
ties also exhibited by tau in the AD brain. Amyloid fibril 
formation may therefore be a cause of abnormal tau 
phosphorylation in AD. 
Introduction 
The neuropathology of Alzheimer's disease (AD) is charac- 
terized by extensive neuronal loss and the presence of 
two different types of fibrillar deposits, amyloid plaques 
and neurofibrillary tangles (reviewed in Yankner and Mes- 
ulam, 1991). Mature amyloid plaques are composed of a 
core of ~-amyloid (13A) surrounded by dystrophic neurites 
and an infiltrate of reactive astrocytes and microglia. Neu- 
rofibrillary tangles are intracellular bundles of straight or 
paired helical filaments that form in the cytoplasm of de- 
generating neurons. Considerable evidence suggests that 
the major constituent of paired helical filaments (PHFs) is 
hyperphosphorylated tau that self-associates via its micro- 
tubule-binding domain (Grundke-lqbal et al., 1986; Kosik 
et al., 1986; Wood et al., 1986; Greenberg and Davies, 
1990; Ksiezak-Reding and Yen, 1991; Lee et al., 1991). 
The cause of aberrant au phosphorylation leading to PHF 
formation in the AD brain is unknown. 
The 13A in amyloid plaques is derived by proteolytic 
cleavage of the amyloid precursor protein (APP; Kang et 
al., 1987). Soluble 13A is produced during the normal me- 
tabolism of APP by a variety of cell types in culture and 
is present in cerebrospinal fluid and plasma (Haass et al., 
1992; Seubert et al., 1992; Shoji et al., 1992; Busciglio 
et al., 1993a). Several lines of evidence suggest that I~A 
accumulation is a central event in the pathophysiology 
of AD. First, genetic studies of families with autosomal 
dominant inheritance of AD have demonstrated several 
mutations in APP which flank the proteolytic leavage sites 
that give rise to 13A (reviewed by Haass and Selkoe, 1993). 
One inherited mutation associated with familial AD in Swe- 
den increases 13A production by severalfold (Citron et al., 
1992; Cai et al., 1993). Another inherited mutation at APP 
codon 717 increases production of the longer and more 
amyloidogenic 42 amino acid form of J3A (Suzuki et al., 
1994). A second line of evidence is the high propensity 
of individuals with Down's syndrome to develop AD by 
middle age, presumably owing to the overexpression of 
APP associated with trisomy 21. Third, the fibrillar form of 
13A present in neuritic plaques in the AD brain is neurotoxic 
(Lorenzo and Yankner, 1994). 
Following the initial observation that 13A is neurotoxic 
(Yankner et al., 1990), several studies showed a strong 
correlation between ~A neurotoxicity and the aggregation 
state of the peptide (Pike et al., 1991; Busciglio et al., 1992; 
Mattson et al., 1993). We have recently demonstrated that 
aggregation by itself is not sufficient, but rather that fibril 
formation is required for neurotoxicity (Lorenzo and Yank- 
ner, 1994). The neurotoxicity of fibrillar [3A is associated 
with dramatic morphological alterations in rat and human 
neurons, including neuronal shrinkage and severe axonal 
and dendritic dystrophy (Yankner et al., 1990; Pike et al., 
1992; Busciglio et al., 1993b). Similar dystrophic changes 
in neuritic morphology occur in the AD brain in neurons 
that develop neurofibrillary pathology. A key biochemical 
event underlying this phenomenom is the hyperphosphor- 
ylation of tau (for review, see Lee and Trojanowski, 1992; 
Goedert, 1993; Mandelkow and Mandelkow, 1993). 
A central issue in the pathogenesis of AD is the rela- 
tionship between amyloid plaque formation and the de- 
velopment of neurofibrillary changes in the neuronal 
cytoskeleton. To determine whether 13A can alter the 
phosphorylation state of tau, we examined primary cul- 
tures of rat and human neurons exposed to fibrillar and 
nonfibrillar ~A using monoclonal antibodies that distin- 
guish phosphorylation-dependent epitopes present in 
PHFs. Fibrillar 13A induced a dramatic increase in tau phos- 
phorylation. The 13A-induced phosphorylated tau resem- 
bled PHF-associated tau in its localization to the neuronal 
somatodendritic ompartment and inability to bind to mi- 
crotubules. 
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Figure 1. Fibrillar ~A Induces the PHF-1 An- 
tigen 
(A and C) Vehicle; (B, D, and E) fibrillar ~A. 
Primary rat hippocampal cultures were treated 
for 4 days with vehicle or 20 p.M fibrillar ~A, and 
immunofluorescence staining was performed 
with the rnonoclonal ntibodies PHF-1 (A-D) 
and AP20 (to MAP2; E). PHF-1 irnmunoreactiv- 
ity in control cultures is confined to axons (A 
and C). Note that treatment with fibrillar ~A 
markedly increases PHF-1 irnrnunoreactivity 
(B) and results in accumulation ofthe PHF-1 
antigen in the sornatodendritic compartment, 
as determined by double labeling with PHF-1 
(D) and anti-MAP2 (E). Bars, 40 ~rn (A and B), 
10 ~.m (C-E). 
Results 
Fibrillar pA Induces Tau Phosphorylation at 
PHF-Associated Epitopes 
To determine whether ~A can produce some of the bio- 
chemical features of neurofibrillary degeneration, we ana- 
lyzed the microtubule-associated protein tau in primary 
rat hippocampal cultures treated with I~A fibrils, which 
have been shown to mediate I~A neurotoxicity (Lorenzo 
and Yankner, 1994). Rat hippocampal cultures enriched 
in pyramidal neurons were maintained at high cell density 
for 5 days in culture to permit neuronal differentiation and 
were then treated with vehicle, soluble I3A, or fibrillar ~A 
for 4 days. Immunocytochemical analysis was performed 
with the PHF-1 monoclonal antibody, which specifically 
recognizes a tau epitope phosphorylated at Ser-396/Ser- 
404 in PHFs (Greenberg et al., 1992; Lang et al., 1992). 
These tau epitopes are also phosphorylated innormal fetal 
brain neurons (Bramblett et al., 1993; Watanabe et al., 
1993). In cultured rat hippocampal neurons, PHF-1 immu- 
noreactMty was detected predominantly in distal axons. 
The neuronal soma nd dendrites were not labeled (Fig- 
ures 1A and 1C). Treatment with soluble I~A showed the 
same pattern of PHF-1 labeling (data not shown). In con- 
trast, treatment with ~A fibrils resulted in a marked induc- 
tion and altered localization of PHF-1 immunoreactivity 
(Figure 1B). PHF-1 immunoreactivity in neurons exposed 
to ~A fibrils was no longer confined to axons, but now 
also appeared in the somatodendritic ompartment, as 
determined by double labeling with an antibody to microtu- 
bule-associated protein 2 (MAP2; Figures 1D and 1E). Im- 
munocytochemistryoffibrillar~A-treated neuronswith the 
monoclonal antibody AT8, which is specific for a different 
phosphorylation-dependent epitope, also demonstrated 
tau induction in the somatodendritic compartment (data 
not shown). 
To determine whether the induction of tau phosphoryla- 
tion is specifically mediated by the 13A fibril, we compared 
the effects of fibrillar and amorphous-aggregated 13A. For 
these experiments, the 1-42 13A peptide was used be- 
cause it can form amorphous aggregates that are stable 
in cell culture (Lorenzo and Yankner, 1994). Amorphous- 
aggregated 13A did not induce PHF-1 immunoreactivity in 
rat hippocampal cultures, in contrast to 15A fibrils, which 
caused a robust induction (Figure 2). These results indi- 
cate that I~A fibril formation is required for the induction 
of the PHF-1 antigen. 
To confirm that the increased PHF-1 immunoreactivity 
induced by ~A fibrils is due to increased tau phosphoryla- 
tion, the cultures were fixed, permeabilized, and treated 
with alkaline phosphatase in the presence of protease in- 
hibitors prior to imrnunocytochemistry with PHF-I. De- 
phosphorylation with alkaline phosphatase completely 
abolished immunoreactivity with PHF-1 (Figures 3A and 
3B). In contrast, dephosphorylation i creased neuronal 
immunoreactivity with the Tau-1 monoclonal antibody, 
which specifically recognizes the Ser-202 epitope in the 
nonphosphorylated state (Figures 3C and 3D) (Binder et 
al., 1985; Lee et al., 1991; Biernat et al., 1992), consistent 
with the exposure of a tau epitope previously masked by 
phosphorylation. The levels of phosphorylated and non- 
phosphorylated tau were further examined by Western 
blot analysis of neuronal cell lysates. In rat hippocampal 
neurons, a single PHF-l-immunoreactive band at 55 kDa 
was detected that was markedly induced by fibriliar ~A 
(7.4 _+ 0.4-fold increase, mean _+ SEM; n = 3; p< .01), 
but was unaffected by soluble I3A (Figure 4A). Fibrillar ~A 
also markedly induced phosphorylation of tau at an epi- 
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Figure 2. 13A-Induced Tau Phosphorylation Requires Amyloid Fibril 
Formation 
(A) Amorphous aggregated 1-4213A; (B) fibrillar 1-4213A. Rat hippo- 
campal neurons were treated with I~A and then stained with PHF-1. 
Fibrillar 1-42 ~A induces phosphorylated tau, whereas amorphous 
aggregated 1-42 ~A is not different from the control shown in Figure 
1A. Bar, 40 I~m. 
tope recognized by the AT8 monoclonal antibody (Figure 
4A), which is specific for phosphorylation at Ser-202 (Bier- 
nat et al., 1992; Goedert et al., 1993). In contrast, fibrillar 
~A did not significantly alter the level of tau detected by 
the Tau-1 antibody (81% _+ 4% of control), which recog- 
nizes the Ser-202 epitope in the nonphosphorylated state. 
In addition, the levels of MAP2 and tubulin were not signifi- 
cantly altered relative to total cellular protein after treat- 
ment with fibrillar I~A (Figure 4A). These results suggest 
that fibrillar I3A increases the absolute and relative levels 
of tau phosphorylated at epitopes associated with PHFs. 
Fibrillar 13A causes progressive neuronal degeneration 
in high density cultures of rat hippocampal neurons re- 
sulting in an approximately 500/0 loss of neuronal viability 
after 3-4 days (Table 1). To determine whether induction 
of tau phosphorylation is secondary to neuronal degenera- 
tion, neurons treated with 13A fibrils were double labeled 
with the vital dye propidium iodide and with PHF-I .  Pro- 
pidium is selectively taken up into the nuclei of nonviable 
cells due to loss of membrane integrity. Fibrillar ~A in- 
duced tau phosphorylation i  neurons that were morpho- 
logically intact and were not labeled by propidium, indi- 
cating that they were viable (Figure 5). Quantitation of neu- 
ronal viability showed that fibrillar I3A induced the appear- 
ance of PHF-l-immunoreactive tau in the somatodendritic 
compartment prior to significant neuronal degeneration 
and cell death (Table 1). After longer time intervals in cul- 
ture, PHF-l-positive neurons with a degenerative morphol- 
ogy were clearly evident. Thus, induction of tau phosphor- 
ylation and somatodendritic accumulation are an early 
neuronal response to fibrillar 13A that precedes neuronal 
degeneration. 
Fibrillar pA Induces Tau Phosphorylation and 
an Electrophoretic Mobility Shift in Human 
Cortical Neurons 
To determine whether fibrillar 13A also affects tau phos- 
phorylation in human cortical neurons, we examined pri- 
[} ,  .~ 
Figure 3. Phosphatase Sensitivity of the 13A- 
Induced PHF-1 Antigen 
(A and B) P H F-1 antibody; (C and D)Tau-1 anti- 
body. Rat hippocampal neurons treated with 
fibrillar p,A were fixed, permeabilized, and 
stained with the PHF-1 or Tau-1 antibody be- 
fore (A and C) and after (B and D) alkaline phos- 
phatase treatment (as described in Experimen- 
tal Procedures). Note that dephosphorylation 
abolishes taining with PHF-1 and increases 
somatodendritic staining with Tau-l. Bar, 40 pro. 
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Table 1. Tau Phosphorylation and Neurotoxicity in Hippocampal 
Cultures Treated with Fibrillar I~A 
Days of Viable Neurons PHF-1-Positive 
Treatment (%) Cell Somas (%) 
1 100 -+ 7 6 _+ 1" 
2 75 _+ 4* 16 _+ 2** 
4 49 _ 3** 40 _ 4** 
Rat h ippocampal cu Itures were treated with vehicle or 20 p.M fibrillar 6A 
for 1-4 days and scored for neuronal viability or immunocytochemically 
stained with PHF-1 as described in Experimental Procedures. Viable 
neurons are expressed as a percentage of vehicle-treated control cul- 
tures. PHF-l-positive cell somas are expressed as a percentage of 
the number of neurons in ~A-treated cultures. No PHF-l-positive cell 
somas were detected in vehicle-treated control cultures. *p < .05; 
* *p < .001 relative to vehicle control by ANOVA with post-hoc Tukey 
test. 
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Figure 4. Phosphorylation and Microtubule Binding of ~A-Induced Tau 
(A) Western blot analysis of cytoskeletal proteins in rat hippocampal 
neurons treated with .BA. Shown are Western blots of whole-cell ho- 
mogenates (TOTAL) and the insoluble (INSOL) and soluble (SOL) frac- 
tions after Triton X-100 extraction. Hippocampal neurons were treated 
with vehicle (V), 20 p.M soluble 13A (S), or 20 p.M fibrillar ~,A (F). Western 
blot analysis was performed with the moneclonal antibodies PHF-1 
(specific for tau phosphorylated at Ser-396 and Ser-404), AT8 (specific 
for tau phosphorylated at Ser-202), Tau-1 (specific for dephosphory- 
lated Ser-202), AP20 (to MAP2), and DM1A (to ~-tubulin); 20 p.g of 
protein was loaded per lane. Note that fibrillar ~A induces phosphory- 
lated tau that is recovered predominantly in the soluble fraction 
(arrows, PHF-1 and AT8), whereas nonphosphorylated tau and MAP2 
are recovered predominantly in the insoluble cytoskeletal fraction. 
(B) I~A-induced tau does not bind to microtubules. Phosphorylated tau 
in the detergent-soluble fraction f neurons treated with fibrillar ~A 
(shown in [A]) was incubated with preassembled microtubules (molar 
ratio of tubulin:tau, >50:1) as described in Experimental Procedures. 
Microtubule-bound tau was determined by Western blot analysis of 
microtubular pellets with antibodies PHF-1 and T u-1 before (-) and 
after (+) alkaline phosphatase tr atment of tau. Dephosphorylation 
of fibrillar ~A-induced tau restores microtubule binding capacity, as 
indicated by the appearance of Tau-1 immunoreactivity. 
mary cultures of fetal human cortical neurons from 17 
week-gestat ion abortuses. We have previously demon- 
strated that aggregated ~A is toxic to human cortical neu- 
rons in culture (Busciglio et al., 1992, 1993b). Phosphory- 
lated tau is normally present in the distal axons of human 
cortical neurons, as observed for rat hippocampal neurons 
(Figure 1A; Figure 6A). Fibrillar I3A caused a dramatic in- 
duction of PHF-1 immunoreactivity in human cortical neu- 
rons, with accumulation in the somatodendrit ic ompart- 
ment, whereas soluble 13A had no significant effect 
(Figures 6A and 6B). 
Western blot analysis with the PHF-1 antibody showed 
a major 55 kDa band and a minor 58 kDa band in control 
human cortical cultures and cultures treated with soluble 
13A. Fibrillar ~A caused a dramatic induction of PHF-1- 
immunoreact ive tau, with a shift in Mr of the predominant 
tau bands from 55 kDa to 56-59 kDa (Figure 6C). Dephos- 
phorylation completely abolished PHF-1 immunoreactiv- 
ity, confirming that the epitope is phosphorylated. Western 
blot analysis of human cortical neurons with the Tau-1 
antibody showed that fibrillar I3A did not significantly affect 
the level of the nonphosphorylated Ser-202 tau epitope 
in human cortical cultures (Figure 6C). However, alkaline 
phosphatase treatment of the blot revealed an additional 
higher Mr band that was detected by the Tau-1 antibody 
only in cells treated with fibrillar [3A (Figure 6C), providing 
further evidence that 13A-induced tau phosphorylation 
shifts the tau Mr. The higher Mr forms of tau were recog- 
nized to a lesser extent by Tau-1 in dephosphorylated blots 
than by PHF-1 in untreated blots, possibly owing to higher 
levels of phosphorylation of the PHF-1 epitope than of the 
Tau-1 epitope. Thus, in human cortical neurons fibrillar 
13A-induced tau phosphorylation results in a shift in Mr, 
reminiscent of the Mr shift exhibited by phosphorylated 
tau in the AD brain. 
pA-Induced Tau Phosphorylation Inhibits 
Microtubule Binding 
Recent reports suggest that PHF-tau in the AD brain has 
lost the capacity to bind to microtubules (Bramblett et al., 
1993; Biernat et al., 1993; Alonso et al., 1994). To deter- 
mine whether ~A-induced tau is bound to microtubules, 
untreated and fibrillar 13A-treated neurons were extracted 
with Triton X-100 under microtubule-stabil izing conditions. 
Detergent-extracted control cultures of fetal rat hippocam- 
pal neurons showed the normal axonal staining pattern 
with the PHF-1 antibody (Figure 7), indicating that normal 
fetal tau is associated with the detergent-resistant cy- 
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Figure 5. ~A-Induced Tau Phosphorylation Precedes Neuronal Death 
Rat hippocampal neurons treated with fibrillar ~A were double labeled 
with the vital dye propidium iodide and with PHF-I. Bright-field illumina- 
tion shows induction of PHF-1 immunoreactivity (A) in a pyramidal 
neuron (arrow) that excludes propidium iodide, as determined by 
epifluorescence illumination (B). Several surrounding dead cells show 
propidium iodide uptake in the nucleus, Bar, 15 p,m. 
toskeleton. In contrast, detergent extraction completely 
released the 13A-induced tau from the neuronal somato- 
dendritic compartment (Figure 7). In neurons treated with 
fibrillar 15A, axonal PHF-l-immunoreactive tau remained 
after detergent extraction (Figure 7, arrows), suggesting 
that a component of normal fetal tau may still remain in 
13A-treated neurons. To determine whether the soluble 
state of J3A-induced somatodendritic tau could be second- 
ary to 13A-induced disruption of microtubules, we exam- 
ined the cytoskeletal association of MAP2 in 13A-treated 
neurons. In contrast to tau, MAP2 was not released by 
detergent extraction and remained associated with the de- 
tergent-resistant cytoskeleton in the somatodendritic com- 
partment (Figure 7), suggesting that the microtubules are 
intact. 
Western blot analysis confirmed that 13A-induced phos- 
phorylated tau is soluble. 13A-induced tau was recovered 
predominantly in the detergent-soluble fraction and was 
minimally associated with the detergent-resistant cy- 
toskeletal fraction (Figure 4A, arrows). In contrast, non- 
phosphorylated tau detected by the Tau-1 antibody was 
recovered predominantly in the detergent-resistant cy- 
toskeletal fraction, and its level was not significantly af- 
fected by treatment with fibrillar I3A(Figu re 4A), suggesting 
that 13A does not prevent he association of nonphosphory- 
lated tau with microtubules. In addition, MAP2 was recov- 
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Figure 6. Fibrillar ~A Induces Tau Phosphorylation and a Shift in Elec- 
trophoretic Mobility in Human Cortical Neurons 
(A and B) Human fetal cortical cultures were treated with 20 p,M soluble 
~A (A) or fibrillar ~A (B). Note that fibrillar ~A markedly induces PHF-1 
immunoreactivity in the somatodendritic compartment. Bar, 40 ~m. 
(C) Western blot analysis of whole-cell lysates of human cortical cul- 
tures treated with soluble ~A (S) or fibrillar I~A (F). Western blot analysis 
was performed with the PHF-1 and Tau-1 antibodies. AP denotes 
samples treated with alkaline phosphatase on the blot prior to immuno- 
labeling. Also shown is the fetal tau species in a homogenate of 17 
week-gestation fetal cerebral cortex (C). 
ered predominantly in the detergent-resistant fraction, and 
its level was unaffected by fibrillar 13A (Figure 4A). These 
results suggest that I~A induces a phosphorylated form of 
tau that is not bound to microtubules. 
To confirm that 13A-induced tau is soluble because of a 
loss of microtubule binding capacity, binding assays to 
purified, preassembled microtubules were performed. 13A- 
induced phosphorylated tau was recovered from the solu- 
ble fraction of detergent-extracted cells and added to pre- 
assembled microtubules in vitro under conditions of 
Neuron 
884 
+#A 
CONTROL CYTOSKELETON Figure 7. ~A-Induced Phosphorylated Tau Is 
Not Bound to the Cytoskeleton 
Rat hippocampal neurons were incubated in 
the absence (-13A) or presence (+~A) of fibrillar 
~A. Shown are intact neurons (CONTROL) and 
neurons extracted with Triton X-100 under mi- 
crotubule-stabilizing conditions (CYTOSKELE- 
TON) as described in Experimental Proce- 
dures. Immunocytochemistry was performed 
with antibody PHF-1 or AP20 (to MAP2) as des- 
ignated. Normal fetal tau is localized to axons 
and is not released by detergent extraction, in- 
dicating that it is bound to microtubules. Infi- 
brillar I~A-treated neurons, PHF-l-immunore- 
active tau is released from the somatodendritic 
compartment, but axonal tau remains bound 
(arrows). MAP2 is bound to the somatoden- 
dritic cytoskeleton of fibdllar 13A-treated neu- 
rons, indicating that microtubules are intact. 
Bar, 40 pm. 
+pA 
microtubule xcess. The 13A-induced tau did not bind to 
microtubules (Figure 4B, negative [-] lanes). After dephos- 
phorylation with alkaline phosphatase, the ability of 13A- 
induced tau to bind to microtubules was restored, as deter- 
mined by its recovery in the microtubule-containing pellet 
(Figure 4B, positive [+] lanes). Microtubule-bound tau lost 
its immunoreactivity with PHF-1 and became immunore- 
active with the Tau-1 antibody, confirming that it was de- 
phosphorylated. These results indicate that tau phosphor- 
ylation induced by fibrillar 13A results in the loss of 
microtubule binding capacity. 
Discussion 
These experiments demonstrate that the ~A fibril induces 
tau phosphorylation. Exposure of primary rat and human 
neurons to fibrillar ~A resulted in increased absolute and 
relative levels of tau phosphorylated at Ser-202 and Ser- 
396/Ser-404. Previous studies have shown that 13A neuro- 
toxicity is accompanied by the induction of immunoreactiv- 
ity for the AIz-50 antibody (Kowall et al., 1991 ; Takashima 
et a1.,1993; Snow et al., 1994). Although AIz-50 recognizes 
a tau epitope associated with PHFs in the AD brain (Wo- 
Iozin et al., 1986), this antibody is not specific for phosphor- 
ylated derivatives of tau (Ksiezak-Reding et al., 1990; 
Goedert et al., 1991). In contrast, the PHF-1 and AT8 
monoclonal antibodies u ed in this study are specific for 
phosphorylation-dependent tau epitopes present in fetal 
brain and in PHFs (Biernat et al., 1992; Greenberg et al., 
1992; Bramblett et al., 1993; Goedert et al., 1993). 
Normal fetal tau and PHF-tau in the AD brain are phos- 
phorylated at common sites (Kanemaru et al., 1992; Ken- 
essey and Yen, 1993), but PHF-tau is distinguished by 
the extent of phosphorylation and the phosphorylation f
additional sites, which may account for its altered proper- 
ties (Hasegawa et al., 1992; Biernat et al., 1993; Matsuo 
et al., 1994). We observed several differences between 
tau in normal fetal neurons and in neurons treated with 
fibrillar 13A. First, fibrillar 13A increased the level of phos- 
phorylated tau and, in human cortical neurons, caused a 
shift to higher Mr forms of phosphorylated tau. The higher 
Mr phosphorylated forms normally represent only a small 
fraction of the phosphorylated tau in fetal human cortical 
neurons, but after exposure to fibrillar I~A, the higher M, 
forms become the predominant phosphorylated tau spe- 
cies. Thus, fibrillar 13A causes hyperphosphorylation f tau 
in human cortical neurons. Second, fibrillar 13A markedly 
increased the accumulation of phosphorylated tau in the 
somatodendritic compartment. Similarly, in the AD brain 
the normal axonal localization of tau (Binder et al., 1985; 
Kosik et al., 1988) is altered with the appearance of tau 
in the somatodendritic ompartment (Kowall and Kosik, 
1987; Ihara, 1988; McKee et al., 1989; Delacourte et al., 
1990). Third, 13A-induc.ed tau appears to be incapable of 
binding to microtubules. These properties of ~A-induced 
tau are similar to those exhibited by PHF-tau in AD. How- 
ever, immunocytochemical analysis of 13A-treated cultures 
did not provide evidence of neurofibrillary tangle forma- 
tion. The development of PHFs leading to neurofibrillary 
tangle formation may require additional age-related fac- 
tors not present in fetal cultures. 
PHF-tau does not bind to microtubules or effectively pro- 
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mote microtubule assembly, whereas fetal phosphory- 
lated tau binds to microtubules and promotes microtubule 
assembly (Bramblett et al., 1993; Biernat et al., 1993; Lu 
and Wood, 1993; Yoshida and Ihara, 1993; Alonso et al., 
1994). We have observed a similar dichotomy for I~A- 
induced phosphorylated tau and fetal phosphorylated tau. 
The phosphorylated tau induced by fibrillar I~A is not bound 
to microtubules in whole-cell preparations and does not 
bind to isolated microtubules in vitro. In contrast, the phos- 
phorylated tau in untreated fetal neurons is not released 
by detergent extraction, suggesting that it may be bound 
to microtubules in the axonal cytoskeleton. Interestingly, 
detergent extraction of I~A-treated neurons selectively re- 
leased the induced tau in the somatodendritic ompart- 
ment but not in axons, suggesting that the latter may be 
normal fetal tau. Thus, normal fetal phosphorylated tau 
appears to be mostly bound to microtubules, whereas 13A- 
induced tau is not associated with microtubules. In this 
respect, 13A-induced tau is more similar to PHF-tau than 
to normal fetal phosphorylated tau. 
The ability of I~A-induced tau to bind to m icrotubules was 
restored by dephosphorylation, indicating that ~A-induced 
phosphorylation is responsible for the inhibition of microtu- 
bule binding. However, it is unclear whether the phosphor- 
ylation sites recognized by the PHF-1 and AT8 antibodies 
are solely responsible for the absence of microtubule 
binding. Phosphorylation of Ser-396, the PHF-l-immuno- 
reactive epitope, is present in both normal fetal tau and 
13A-induced tau, yet the two differ in cellular distribution 
and cytoskeletal association. This difference may be due 
to I~A-induced phosphorylation of other sites that are not 
phosphorylated in normal fetal tau, such as Ser-262 (Ha- 
segawa et al., 1992; Biernat et al., 1993). The resultant 
loss of microtubule binding capacity may prevent the 
transport of tau into the axon, causing accumulation of tau 
in the somatodendritic ompartment. Loss of microtubule 
binding may also contribute to the neurotoxicity of fibrillar 
13A by destabilizing microtubules, resulting in neuritic dys- 
trophy and impaired axonal transport. In addition to alter- 
ing the properties of tau, fibrillar 13A also increased the 
absolute level of tau, suggesting that as neurons degener- 
ate tau continues to accumulate, which may in turn accel- 
erate neuronal death. 
The effects of fibrillar I3A on tau phosphorylation could 
be the result of increased kinase or decreased phospha- 
tase activity (Matsuo et al., 1994). It has been shown that 
13A can increase the activity of several different protein 
kinases that could potentially phosphorylate tau, including 
protein kinase C (Chauhan et al., 1991), casein kinases 
I and II (Chauhan et al., 1993), and tau protein kinase I 
(Takashima et al., 1993). It has also been reported that 
13A neurotoxicity can be prevented by inhibiting the synthe- 
sis of tau protein kinase I using antisense oligonucleotides 
(Takashima et al., 1993). These results, and our finding 
that increased tau phosphorylation is an early neuronal 
response to fibrillar I~A, raise the possibility that altered 
protein kinase or phosphatase activity may play an im- 
portant role in the signal transduction system that under- 
lies hA neurotoxicity. 
Our results provide a potential ink between the two pri- 
mary histopathological features of the AD brain, amyloid 
plaques and neurofibrUlary tangles. Amyloid deposits in 
the brain evolve from a diffuse form containing amorphous 
aggregated 13A and some fibrils to a compact form con- 
taining a high density of amyloid fibrils (reviewed in Yank- 
ner and Mesulam, 1991). Diffuse amyloid appears to be 
inert, whereas compacted fibrillar amyloid is associated 
with dystrophic neurites and neurofibrillary tangles. This 
observation in vivo is consistent with our finding in cell 
culture that fibril formation is required for 13A neurotoxicity 
(Lorenzo and Yankner, 1994) and the induction of tau 
phosphorylation. Increased tau phosphorylation may also 
induce further production of 13A, thereby increasing the 
rate of amyloid fibril formation in a positive feedback loop 
(Shin et al., 1993). Recent studies suggest that different 
amyloid fibrils (Lorenzo et al., 1994; Lorenzo and Yankner, 
1994) and amyloidogenic peptides (Forloni et al., 1993; 
May et al., 1993) possess a common cytopathic activity. 
We have found that amyloid fibrils composed of diabetes- 
associated amylin also induce tau phosphorylation at Ser- 
396/Ser-404, with somatodendritic accumulation similar 
to that in fibrillar ~A-treated neurons (A. L., J. B., and 
B. A. Y., unpublished ata). This observation supports the 
hypothesis of a common amyloid fibril-mediated mecha- 
nism and raises the possibility that other amyloidoses of 
the brain, such as the prion-related disorders, may also 
induce abnormal tau phosphorylation. 
Neurofibrillary tangles and dystrophic neurites can ap- 
pear in regions of the AD brain seemingly devoid of amy- 
Ioid deposits (reviewed in Goedert, 1993). In addition, the 
onset of dementia correlates more closely with synapse 
loss and the number of neurofibrillary tangles than with 
the total amyloid plaque burden in the brain (Terry et al., 
1991; Arriagada et al., 1992). However, our results sug- 
gest that plaque formation is not necessary for 13A-induced 
neurotoxicity and tau hyperphosphorylation. In primary 
cultures of human neurons, I~A fibrils induce neurotoxicity 
and tau phosphorylation without evidence of plaque forma- 
tion. This observation suggests that early stages of J3A 
fibril deposition may lead to neurofibrillary pathology in 
the absence of plaques. The mature plaque may therefore 
reflect a very late stage of 13A fibril accumulation that is 
evident histologically only after considerable neuronal 
damage has already occurred. It is also possible that I~A 
causes neurofibrillary pathological changes in the immedi- 
ate vicinity of plaques but is not the cause of neurofibrillary 
pathology in other plaque-free regions of the AD brain. 
It remains to be determined whether amyloidosis is the 
primary cause of neurofibrillary pathology in the AD brain 
or one of several neuronal insults that together result in 
dementing illness. 
Experimental Procedures 
Cell Culture 
Primary rat hippocampal cultures were established from embryonic 
day 18 fetuses as described previously (Lorenzo and Yankner, 1994) 
at 1 x 106 cells per 60 mm plate on polylysine-coated glass coverslips. 
Primary human cortical cultures were established from 15-17 week- 
gestation human fetal abortuses as described previously (Busciglio et 
al., 1993b). The protocol for tissue procurement complied with federal 
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and institutional guidelines for fetal research. Rat and human primary 
cultures were plated in DMEM with 10% supplemented calf serum 
(HyCIone). After 24 hr, the medium was changed to serum-free DMEM 
with N2 supplements (GIBCO). A 30°/0 change of medium was per- 
formed every 3 days. 
Peptides and Treatments 
Synthetic 13A peptides were obtained from Bachem (lots ZL600, ZL243, 
and ZL573) and from Sigma (lot 93H4950). The 1-40 I3A peptide was 
dissolved in double-distilled H=O to 3 mg/ml, further diluted in PBS to 
1.5 mg/ml, and used immediately (soluble form) or after preincubation 
at 37°C for 2-5 days to preaggregate the peptide. The predominant 
aggregated form of 1-40 I~A in this preparation is the amyloid fibril, 
as determined by electron microscopy and Congo red birefringence 
(Lorenzo and Yankner, 1994). Soluble or fibrillar I~A was added directly 
to culture medium to a final concentration of 20 pM; control cultures 
received the same volume of PBS vehicle. Peptides were added to 
rat hippocampal cultures 4 days after plating and incubated for 4 days. 
Peptides were added to high density human cortical cultures after 35 
days in culture and incubated for 14 days as described previously 
(Busciglio et al., 1993b). In some experiments, fibrillar and amorphous 
aggregates of 1-42 ~A were generated as described (Lorenzo and 
Yankner, 1994) and added to cultures. 
Immunocytochemistry 
The following primary antibodies were used in this study: a monoclonal 
antibody to MAP2 (clone AP20; 1:500; Sigma), a monoclonal antibody 
to dephosphorylated epitopes of tau at Ser-199 and Ser-202 (Tau-1; 
1:200; Boehringer Mannheim; Binder et al., 1985), a monoclonal anti- 
body to a phosphorylated tau epitope at Ser-202 (AT8; 30 i~g/ml; Bier- 
nat et al., 1992), a monoclonal antibody to phosphorylated tau epitopes 
at Ser-396 and Ser-404 (PHF-1; 1:1000; Greenberg et al., 1992), and 
a monoclonal antibody to a-tubulin (clone DM1A; 1:2000; Sigma). 
Cultures were fixed in 4% paraformaldehyde, 0.12 M sucrose in PBS 
for 30 min and permeabilized with 0.2% Triton X-100. For immunocy- 
tochemistry, fixed cells were incubated with primary antibody for 12 
hr at 4°C. The cells were then incubated with biotinylated anti-mouse 
IgG (1:200) for 1 hr at 20°C, followed by ExtrAvidin-peroxidase (1: 
200) and diaminobenzidine. For immunofluorescence, rhodamine- or 
fluorescein-conju gated anti-mouse IgG secondary antibodies (1:100; 
1 hr at 20°C) were used. Sequential labeling for PHF-1 and MAP2 
was performed by first incubating with PHF-1 and a biotin-conjugated 
secondary antibody followed by Avidin-Texas red, and then incubating 
with anti-MAP2 and a fluorescein-conjugated secondary antibody. De- 
phosphorylation was performed by incubating fixed and permeabilized 
cells with Escherichia coil alkaline phosphatase (50 U/ml; Sigma) and 
bovine intestinal alkaline phosphatase (50 U/ml; Boehringer Mann- 
helm) in 50 mM Tris-HCI (pH 8.0), 0.1 mM EGTA, and the protease 
inhibitors phenylmethylsulfonyl fluoride (1 mg/ml), aprotinin (10 I~g/ 
ml), leupeptin (20 mg/ml), and pepstatin (20 ~g/ml) for 12 hr at 37°C. 
Neuronal Counts 
To assess cell viability, living cultures were incubated with 5 p_g/ml 
propidium iodide for 10 min, washed with PBS, and then fixed and 
processed for immunocytochemistry. Viable neurons exclude propid- 
ium iodide. Scoring of viable neurons was performed in 14-20 micro- 
scopic fields (0.4 mm 2 per field) per culture in duplicate cultures using 
bright-field illumination to detect PHF-l-peroxidase staining and 
epifluorescence to detect propidium iodide uptake. More than 380 
neurons were scored in control cultures. 
Preparation of Cytoskeletal Fractions 
Preparation of the detergent-resistant cytoskeleton from neurons in 
culture was performed as described (Caceres et al., 1986). Living cul- 
tures were washed with prewarmed microtubule-stabilizing buffer 
(0.13 M HEPES [pH 6.9], 2 mM MgCI2, 10 rnM EGTA) and then ex- 
tracted in the same buffer with 0.2% Triton X-100 for 2 rain at 37°C. 
For immunocytochemistry, the cultures were fixed and staining was 
performed on the Triton-resistant neuronal cytoskeleton remaining on 
the coverslip. For Western blot analysis, cultures grown in 60 mm 
culture dishes were extracted with 2 ml of 0.2% Triton X-100/microtu- 
bule stabilizing buffer, and the insoluble cytoskeletal fraction on the 
coverslip was harvested in SDS-reducing sample buffer and boiled. 
The Triton-soluble fraction was clarified by centrifugation at 
100,000 x g for 30 min. 
Western Blot Analysis 
Cultures were washed with PBS, suspended in SDS-reducing sample 
buffer using a cell scraper, and boiled for 5 rain. The extract was 
clarified by centrifugation at 100,000 x g for 30 min. The supernatants 
were collected, and the protein content was determined by the 
Bio-Rad protein assay. Protein (20 ixg per lane) was loaded in 4%- 
20% gradient SDS-polyacrylamide gels and electrotransferred to ni- 
trocellulose. The blots were blocked in 5% nonfat dry milk, incubated 
with primary antibody for 12 hr at 4°C, and then incubated with a 
peroxidase-conju gated secondary antibody (1:1000; Amersham) for 1 
hr. Immunodetection was performed by enhanced chemilumines- 
cence (Amersham). For dephosphorylation, the nitrocellulose blots 
were treated with 25 U/ml E. coil alkaline phosphatase in 50 mM Tris- 
HCI [pH 8.0], 0.1 mM EDTA and the protease inhibitors described 
above for 1 hr at 67°C, followed by incubation with primary antibody. 
Immunoprecipitation 
The Triton-soluble fraction of cytoskeletal preparations was incubated 
with the Tau-1 (1:200) or PHF-1 (1:500) antibody in the presence 
of the protease inhibitors described above for 4 hr at 4°C and then 
immunoprecipitated with protein A-Sepharose (Pharmacia). The pro- 
tein A-Sepharose was washed with PBS, resuspended in SDS- 
reducing sample buffer, boiled, and resolved by SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE). Proteins were then electrotrans- 
ferred to nitrocellulose for Western blotting. 
Microtubule Binding Assay 
Tubulin was isolated by phosphocellulose chromatography from 
twice-cycled bovine brain microtubules as described (Williams and 
Dietrich, 1979; Murthy and Flavin, 1983). Purified tubulin was then 
assembled into microtubules by incubation in assembly buffer (0.1 M 
MES [pH 6.8], 0.5 mM MgSO4, 1 mM EGTA, 2 mM dithiothreitol, 2 
mM GTP, 20 IxM taxoi) for 30 min at 37°C (Vallee, 1982; Bramblett 
et al., 1993). Preassembled microtubules (1 mg/ml)were then incu- 
bated at 37°C for 30 min with phosphorylated or dephosphorylated 
Triton-soluble fractions from cytoskeletal extractions of J~A-treated cul- 
tures. The molar ratio of tubulin:tau was >50:1 as determined by the 
concentration of heat-stable tau. Microtubules were centrifuged at 
50,000 x g for 30 min, and the pellet was washed by additional centrifu- 
gation at 50,000 x g in assembly buffer/10% sucrose. Microtubules 
were resuspended in SDS-reducing sample buffer, resolved by SDS- 
PAGE, and electrotransferred to nitrocellulose for Western blotting 
with antibody PHF-1 or Tau-1. To dephosphorylate I~A-induced tau, 
the Triton-soluble cell extract was adjusted to pH 8.0 with NaOH and 
incubated with 25 U/ml E. coil alkaline phosphatase (Sigma) in the 
presence of the protease inhibitors described above for I hr at 67°C. 
The pH was then adjusted to 6.8 for the microtubule binding assay. 
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